Sagar Bhagwat, MBA, MS

CRS:

BJMC

Role:

Administrative and Finance

Position:

Senior Grants and Contracts Analyst

Mr. Bhagwat is the Senior Grants and Contracts Analyst for Johns Hopkins Center for Clinical Global Health Education (CCGHE) and manages the financial activities of the center along with the Fiscal Operations Manager. He works on all aspects of sponsored research pre and post award, including development and management of federal, state, private, and foundation grants/contracts. He is the primary contact for all outgoing CCGHE subcontracts and works closely with international collaborators in India, Uganda, United Kingdom as well as domestic collaborators within the US.
 
Mr. Bhagwat is a part of the CCGHE leadership group that provides financial/administrative support and oversight to the Johns Hopkins entities in India (Johns Hopkins India Pvt. Ltd & Johns Hopkins India Foundation). He works closely with external funding agencies such as US National Institutes of Health (NIH), CRDF Global, Maryland Department of Health (MDH) among others and internally with the Office of Research Administration (ORA), the Office of Sponsored Projects and Shared Services (SPSS), the Department Finance Office at the Johns Hopkins University School of Medicine.
 
He joined Johns Hopkins in 2016 with several years of accounting and finance experience. He received a dual Master’s degree in Business Administration (MBA in Operations Management) and Science (MS in Chemical & Biomedical Engineering) from the Cleveland State University.

Categories

Leadership Committees
CRS
Roles

Clinical Trials

A5342: Evaluating the Safety, Tolerability, and Effect of a...

The purpose of this study is to evaluate the safety, tolerability, and effect of an experimental human monoclonal antibody...

Read More

A5300B/I2003B/PHOENIX, Protecting Households On Exposure to...

This study will compare the efficacy and safety of 26 weeks of delamanid (DLM) versus 26 weeks of isoniazid (INH) for preventing...

Read More

A5253: Sensitivity and Specificity of Mycobacterium...

An estimated 3 million HIV-infected individuals will enter programs for antiretroviral (ARV) treatment in the coming year, with...

Read More

P2026: Pharmacokinetic Properties of Antiretroviral and...

IMPAACT P1026s, the predecessor of this study, was first approved in 2003. P1026s enrolled over 1000 pregnant/postpartum women,...

Read More

A5327: Sofosbuvir + Ribavirin w/o Interferon for Treatment...

A5327 SWIFT-C is a Phase I, open-label, two-cohort clinical trial, in which between 44 and 50 acutely HCV-infected HIV-1...

Read More